May 8, 2024Clinical Gastroenterology and Hepatology22 citationsOpen Access
View Full PaperOzanimod in Patients With Moderate to Severe Ulcerative Colitis Naive to Advanced Therapies
Key Points
Key points are not available for this paper at this time.
Abstract
The pivotal phase 3 True North (TN) study demonstrated the efficacy and safety of ozanimod in patients with moderately to severely active ulcerative colitis. This analysis assessed ozanimod during TN and the ongoing open-label extension (OLE) in patients with active disease who were naive to advanced therapies (ATs).